FDA
approval
· 2022-12-19
FDA Approved: BEOVU — Supplemental Application (Novartis Pharmaceuticals Corporation)
Summary
The FDA approved a supplemental application for BEOVU (brolucizumab) from Novartis Pharmaceuticals Corporation. This action approves an expanded or updated use …
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for BEOVU (BROLUCIZUMAB)